Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

Overview of attention for article published in BMC Cancer, July 2009

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

So far, Altmetric has seen 5 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 1 additional patents.